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ABSTRACT 
 
The Wharton’s jelly of the umbilical cord is believed to be a source of mesenchymal stem 
cells (MSCs) which can be therapeutically applied in degenerative diseases. 
In this study, we investigated the immunomodulatory effect of umbilical cord derived-
mesenchymal stem cells (UC-MSCs) and bone marrow-derived-mesenchymal stem cells 
(BM-MSCs) on differentiation, maturation, and endocytosis of monocyte-derived dendritic 
cells in a transwell culture system under laboratory conditions. Monocytes were differentiated 
into immature dendritic cells (iDCs) in the presence of GM-CSF and IL-4 for 6 days and 
then differentiated into mature dendritic cells (mDCs) in the presence of TNF-α for 2 days. 
In every stage of differentiation, immature and mature dendritic cells were separately co-
cultured with UC-MSCs and BM-MSCs.  
The findings showed that UC-MSCs and BM-MSCs inhibited strongly differentiation and 
maturation of dendritic cells at higher dilution ratios (1:1). The BM-MSCs and UC-MSCs 
showed more inhibitory effect on CD1a, CD83, CD86 expression, and dendritic cell 
endocytic activity, respectively. On the other hand, these cells severely up-regulated CD14 
marker expression.  
We concluded that UC-MSCs and BM-MSCs could inhibit differentiation, maturation 
and endocytosis in monocyte-derived DCs through the secreted factors and free of any cell-
cell contacts under laboratory conditions. As DCs are believed to be the main antigen 
presenting cells for naïve T cells in triggering immune responses, it would be logical that 
their inhibitory effect on differentiation, maturation and function can decrease or modulate 
immune and inflammatory responses. 
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INTRODUCTION 
 
Stem cells, according to their origin, are 
categorized to Embryonic and Adult Stem cells.1 
Mesenchymal stem cells (MSCs) are the most 
important source of adult stem cells and have 
attracted the attention of lots of researchers. These 
cells participate in regeneration of tissues with 
mesenchymal origin such as bone, cartilage, muscle, 
tendon and adipose tissue. In addition, they play a 
supportive role to bone marrow hematopoietic 
cells.2-4 MSCs express negligible levels of MHC 
class I and no MHC class II, and are negative for 
hemopoietic and endothelial markers (CD45, CD34, 
CD31) and positive for other markers such as CD90, 
CD73, CD105, CD106 and CD44.5-8 Bone marrow 
has been the most important source of MSCs during 
the recent years. Lately, scientists found out that 
MSCs can be collected from resources such as 
Wharton’s jelly of the umbilical cord.9-12 
The Wharton’s jelly (WJ) is, in fact, a gelatin 
substance inside the umbilical cord which contains a 
significant amount of mucopolysacharide 
(hyalorunic acid), chondroitin sulfate, and fibroblast 
cells. This mucoid tissue protects the veins of the 
umbilical cord.13,14 The WJ secretes IGF (Insulin like 
growth factor), PDGF (platelet-derived growth 
factor), EGF (Epidermal growth factor) and TGF-β 
(Transforming growth factor-beta) with capability to 
induce proliferation and growth of the other 
cells.15,16 The Wharton's jelly of the umbilical cord 
derived-mesenchymal stem cells (UC-MSC) express 
MSC markers such as CD90, CD73, CD105, CD106 
and do not express hemopoietic and endothelial 
markers such as CD45, CD34 and CD31.9, 10 They 
can be differentiated in in vitro conditions to 
neuromuscular, 17,18 cardiac, hepatocyte,19,20 skin,21 
cartilaginous and bone cells.22,23 These cells, are 
therefore, classified as pluripotent cells. 
The WJ of the umbilical cord comparing to 
mature tissues such as brain, bone marrow, adipose 
tissue and circulating blood is much more accessible 
for collection of MSCs. In addition, easy 
accessibility, low antigenicity, low ethical concerns, 
embryo-like properties, high capacity of 
proliferation and differentiation to other various cell  
lineages, tissue regeneration along with 
immunomodulatory effects on immune system, low 
risk of viral infectivity and pain-free collection 
prioritized UC-MSCs a better therapeutic application 
compared to Bone marrow derived-MSCs (BM-
MSCs).11,24,25 
Dendritic cells are the major antigen presenting 
cells which originate from both CD34-derived and 
monocyte-derived dendritic cells by induction of 
Granulocyte Macrophage-Colony Stimulating Factor 
(GM-CSF) and Interleukine-4 (IL-4).26,27 They 
particularly play indispensable role in priming and 
directing naïve T cell immune responses.28,29 
Regarding the produced cytokines and 
environmental stimuli, dendritic cells are able to 
initiate and drive different types of immune 
responses. Based on the maturation and growth 
conditions, they can promote primary or secondary 
responses as well as T-regulatory (TReg) cell 
regeneration and T cell tolerance.28-33 In the previous 
studies on laboratory models, BM-MSCs have been 
shown to possess suppressive effects on T cells and 
their immune responses through secretion of factors 
like TGF-β, prostaglandin E2 (PGE2) and 
Hepatocyte growth factor (HGF) which can be the 
cause of host unresponsiveness, and therefore 
possible role in graft protection.6,34,35 The 
immunomodulatory effect of MSCs on immune 
responses can be contributed to the capacity of 
dendritic cells in producing tolerogenic antigen 
presenting cells thorough functional alterations. 
Accordingly, the main aim of this study was to 
investigate immunomodulatory effects of Human 
UC-MSCs on monocyte-derived dendritic cells 
(indirect contact with Transwell culture systems).  
 
MATERIALS AND METHODS 
 
Collection and Primary Cultivation of MSCs 
Extracted from the Wharton’s Jelly of the 
Umbilical Cord by Collagenese Assay 
Umbilical cord samples were obtained after the 
delivery of normal-term babies with informed 
consent of the healthy mothers .Then the human 
umbilical cords were stored in sterile Hank's 
Balanced Salt Solution (HBSS) supplemented with 
100 IU/ml penicillin, 100 µg/ml streptomycin, and 
0.025 µg/ml Amphotericin B to be transported to cell 
culture laboratory. Next, the umbilical cords were 
washed with 75% ethylic alcohol for 30 seconds and 
the blood vessels were scraped off and then the 
Wharton’s jellies cut up in 2-3mm pieces. The pieces 
then were centrifuged in Dulbecco's Modified Eagle 
Medium (DMEM) media (Gibco) at 250g for 5 
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minutes and the isolated cells were incubated in 
DMEM media containing antibiotic-antimycotic 
(Invitrogen), and collagenase (1mg/ml) for 16-18 
hours in 5% Co2 in a 37 ºC incubator. The adhered 
cells were trypsinized (0.25%) and transferred to the 
flasks containing DMEM-F12 media with fetal 
bovine serum (FBS) 10% (Gibco) and incubated for 
1-2 weeks in 5% Co2 at 37ºC. The media were 
changed every 3-4 days. At this stage, three tests 
were applied: 1) Viability test (more than 95%), 2) 
Differentiation to adipocyte and osteocyte, 3) Cell 
surface marker expression (CD45, CD34, CD90, 
CD105, CD73, and HLA-DR) through flow 
cytometery analysis (Becton Dickinson) to confirm 
MSC cell profile. Finally, we froze the UC-MSCs 
cryogenically (10% DMSO and 90% FBS) for later 
use. 
 
Collection and Primary Cultivation of BM-MSCs  
We used BM-MSCs as control to be compared to 
UC-MSCs. Bone marrow samples were obtained 
after informed consent from harvests of healthy 
donors for allogeneic transplantation. Mononuclear 
cells were centrifuged at 400g for 5 minutes in 
phycol (1.077 g/ml; Invitrogen). Next, the cells were 
washed with phosphate-buffered saline (PBS) and 
cultured at 25cm2 SPL flasks in DMEM-LG (Gibco) 
supplemented with 10% FBS, antibiotic-antimycotic 
(Invitrogen) for 2 weeks in 5% Co2 in a 37ºC 
incubator. After 72 hours, unadhered cells were 
washed away with PBS and the culture medium was 
refreshed. The medium was changed every 3-4 days 
to eventually obtain 80% confluent cells. The 
medium was then washed with PBS and the adhered 
MSC cells were treated with Trypsin-EDTA 0.25% 
and washed with PBS and FBS and cultured at 75 
and 175 cm2 flasks. Then, at this stage, three tests 
were applied: 1) Viability test (more than 95%), 2) 
Differentiation to adipocyte and osteocyte, 3) Cell 
surface marker expression (CD45, CD34, CD90, 
CD105, CD73, and HLA-DR) through flow 
cytometery analysis (Becton Dickinson) to confirm 
MSC cell profile. Finally, we froze the BM-MSCs 
cryogenically for later use. 
 
The Differentiation of the UC-MSCs and BM-
MSCs to Adipose Cells 
The isolated and cultivated mesenchymal stem 
cells from bone marrow and the Wharton’s jelly of 
the umbilical cord (80% confluent at passage 2) were 
used to be differentiated to adipocytes. The cultured 
cells in DMEM and FBS 10% were considered as 
control. The MSCs were washed with PBS and 
incubated in DMEM adipogenic differentiation 
medium supplemented with 10% FBS, ascorbate 1-
phosphate (50mg/ml), dexamethasone (10-7 M), 
indomethacine (50mg/ml) and 5µg/ml insulin in 5% 
Co2 at 37ºC for 15 days. The medium was changed 
every 4 days. On the day 15, the cells were washed 
with PBS two times and then fixed in 10% 
formaldehyde for 1 hour. Next, the fixed cells were 
re-washed with water and exposed to Oil Red O 
(0.5% in 99% isoporopanol) for 15 minutes. Finally, 
the cells were washed with water and examined 
under inverted phase contrast microscope 
immediately to show adipogenic differentiation. 
 
The Differentiation of UC-MSCs and BM-MSCs 
to Osteocytes 
The isolated and cultivated MSCs from bone 
marrow and the Wharton’s jelly of the umbilical 
cord (80% confluent at passage) were used to be 
differentiated to osteocytes. The cultured cells in 
DMEM and FBS 10% were considered as control. 
The MSCs were washed with PBS and incubated in 
DMEM osteogenic differentiation medium 
supplemented with 10% FBS, ascorbate 2-phosphate 
(50mg/ml), dexametasone10-8M, B-glycerol 
phosphate (10 mM) in 5% Co2 at 37ºC for 21 days. 
The medium was changed every 4 days. On the day 
21, the cells were washed with PBS two times and  
then fixed in methanol for 10 minutes. Next, the 
fixed cells were stained with 1% alizarin red stain in 
25% ammonia for 10-15 minutes, and washed with 
water two times. Finally, the cells were dried in air 
and examined under inverted phase contrast 
microscope immediately to detect intracellular 
calcium deposition (orange red color) and thereby 
osteogenic differentiation. 
 
The Isolation of Peripheral Blood Monocytes 
(PBMC) by Using the Magnetic-activated cell 
sorting (MACS) Monocyte Isolation Kit  
The blood samples were obtained with 
heparinized sterile syringes from 15 healthy donors. 
Then, the samples were mixed and diluted with the 
equal volume of PBS and PBMC obtained using 
Ficoll-Hypaque (1.077g/ml; Invitrogen). Monocytes 
(more than 96%) were purified from PBMC by using 
the MACS monocyte Isolation kit (Miltenyi Biotec). 
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Different ratios (1:1, 1:2 and 1:10) of the isolated 
cells were co-cultured with the UC-MSCs and BM-
MSCs in six-compartment culture plates.  
 
The Cultivation of PBMC and Differentiation to 
Immature and Mature Dendritic Cells in vitro 
CD14 Microbead acquired monocytes were 
cultured in three series of six-compartment culture 
plates containing whole RPMI-1640 medium (Gibco) 
supplemented with 10% FBS, streptomycin 
(100µg/ml), and penicillin (100u/ml). Then, GM-
CSF (1000u/ml) and IL-4 (500u/ml; R&D) were 
added to all plates and incubated for 6 days in 5% 
Co2 at 37° C to be differentiated to immature 
dendritic cells (iDCs). On day 3, fresh medium with 
the similar content of GM-CSF and IL-4 was added 
to the plates. On day 7, the cells in plate 1 and 2 
were examined for immature dendritic cell surface 
markers (CD1a, CD14, CD80, CD83, CD86 and 
HLA-DR) through flowcytometery and endocytic 
activity through Fluorescein isothiocynate dextran, 
respectively. On day 6, TNF- α (10ng/ml; R&D) as a 
dendritic cell maturation factor was added to the 
third plate. On day 9, the cells in the third plate 
(mature dendritic cells surface markers), were 
analyzed through flowcytometery.  
 
The Co-cultivation of UC- and BM-MSCs with 
Dendritic Cells 
The six-compartment transwell plates with 0.4 
µm pore sizes were used to assure cell contacts 
through their secretions rather than any direct 
physical contacts. With respect to different dilution 
ratios (1:1, 1:2, and 1:10), the collected monocytes 
were added to the lower chambers and the upper 
chambers were occupied with UC-MSCs or BM-
MSCs. To assess surface marker expression profile, 
two separate plates were considered for co-
cultivation of UC-MSCs and BM-MSCs with 
immature dendritic cells. To assess endocytic 
activity, two other separate plates were considered 
for co-cultivation of UC-MSCs and BM-MSCs with 
iDCs. Two more plates were used to co-cultivate UC-
MSCs and BM-MSCs with mature dendritic cells 
(mDCs) to analyze surface marker expression profiles. 
RPMI-1640 supplemented with 10% FBS was used 
as the growth medium. 
 
Dendritic Cell Endocytosis 
With respect to the different dilution ratios (1:1, 
1:2, and 1:10), the collected monocytes were first 
cultured in two transwell plates containing the 
medium supplemented with IL-4 (20ng/ml) and GM-
CSF (30ng/ml) for 6 days to generate iDCs. Next, 
the immature cells were separately co-cultured in 
transwell plates with UC-MSCs and BM-MSCs and 
incubated for 3 days. Then, the cultured iDCs were 
isolated and incubated at 37°C and at 4°C (as 
control) for 1 hour exposed  to FITC-Dextran (1 
mg/mL; molecular weight 40000 MW; Sigma). Next, 
the cells were washed with cold PBS two times to 
stop endocytosis. Finally, they were fixed in 1% 
formalin and analyzed through flowcytometery 
immediately. 
 
Statistical Analysis 
Analytical statistics were performed using the SPSS 
16. According to the quantitative data, Shapiro- Wilk 
test for normality of data distribution was assessed. 
Comparisons between different groups with control 
were performed using the paired sample t test. P values 
less than 0.05 were considered statistically significant. 
 
RESULTS 
 
Comparison between UC-MSC and BM-MSC in 
Proliferation and Size 
We observed that UC-MSCs in addition to higher 
proliferation rate were larger in size and diameter 
compared to BM-MSCs and with increasing the passage 
number (P20) the proliferation rate remained unchanged 
although decreased in BM-MSCs (Figure 1). 
 
Osteogenic Differentiation of UC-MSCs and BM-
MSCs 
The cells in UC-MSC and BM-MSC (date not 
shown) were separately cultured in osteogenic 
differentiation medium for 21 days. The cultured 
cells in DMEM and 10% FBS were considered as 
negative control. On day 21, the cells (calcium 
deposition) were stained with Alizarin Red dye to 
confirm osteogenic patterning (Figure 2a, b). 
 
Adipogenic Differentiation of UC-MSCs and BM-
MSCs 
The cells in UC-MSC and BM-MSC were 
separately cultured in adipogenic differentiation 
medium for 15 days. The cultured cells in DMEM 
and 10% FBS were considered as negative control.  
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a) b) 
Figure 1. Characteristics of UC-MSCs (a) and BM-MSCs (b). The cells possess fibroblast-like morphology.  
 
   
a)       b) 
   
c) d) 
Figure 2. Osteogenic and Adipogenic differentiation of UC-MSCs. 
a) UC-MSCs after 21 days in DMEM-F12 medium with no color change under Alizarin Red S staining (Negative control, 
40x). b) Osteogenic induction in UC-MSCs after 21 days in DMEM-F12 supplemented with growth factors, intracellular 
calcium deposition (orange red) under Alizarin Red S staining in osteocytes (40X). c) UC-MSCs after 15 days in DMEM-F12 
lacking of fat droplets under Oil Red O staining (Negative control, 40x). d) Adipogenic induction in UC-MSCs after 15 days 
in DMEM-F12 supplemented with growth factors, intracellular vacuoles containing fat droplets (dark red) under Oil Red O 
staining in adipocytes (40x). 
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Figure 3. Flow cytometric analysis of UC-MSCs' surface markers. UC-MSCs were cultured in DMEM-F12 supplemented 
with 10% FBS. Then, the cells were analyzed by flowcytometery. Similar results were obtained with BM-MSCs (data not 
shown).  
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Fat vacuoles were microscopically observed in BM-
MSC (data not shown) and the WJ of the umbilical 
cord in adipogenic differentiation medium over 3-4 
days after cultivation and increased in number with 
time such that the cytoplasm of some cells were 
accumulated with such vacuoles at the end of the 
second week. On day 15, the cells were stained with 
Oil Red O to confirm adipogenic patterning (Red 
cytoplasm, Figure 2c, d). 
 
Flow Cytometeric Analysis of Surface-marker 
Expression on UC-MSCs and BM-MSCs  
The UC-MSCs and BM-MSCs were cultured in DMEM-
F12 supplemented with 10% FBS (Passage 2). The 
surface markers including CD73, CD90, CD105, CD34, 
and CD45 were measured by flowcytometery. Our data 
showed that UC-MSCs and BM-MSCs had the same 
surface marker profiles (Figure 3). 
 
UC-MSC Inhibitory Effect on Differentiation and 
Maturation Markers in Monocyte-Derived Dendritic 
Cells 
Monocytes were cultured in medium supplemented 
with GM-CSF and IL-4 for 6 days and then TNF-α for 
2 days at 37°C and 5% Co2 to differentiate to immature  
and mature dendritic cells, respectively. We observed 
that UC-MSCs down-regulated maturation and 
differentiation markers on immature and mature 
dendritic cells and by increasing the cell dilution ratio, 
the inhibitory effect also increased. CD1a surface 
marker was down-regulated in immature and mature 
dendritic cell differentiation stages particularly in 1:1, 
1:2 and 1:10 ratio and 1:1 ratio, respectively, so that 
with rise in cell dilution ratio, the effect augmented and 
vice versa (Figure 4). Also, CD14 surface marker 
expression was up-regulated in immature and mature 
dendritic cell differentiation stages particularly in 1:1, 
1:2 ratio and 1:1 ratio, respectively (Figure 4). 
The costimulatory molecules of CD86/CD80 
expression were down regulated significantly in 1:1 
ratio and 1:1, 1:2 ratio in immature and mature 
differentiation stages, respectively. So that with rise in 
cell dilution ratio the effect augmented and vice versa 
(Figure 5). 
The expression of CD83 and HLA-DR molecules were 
down-regulated significantly particularly in 1:1 ratio 
and 1:1, 1:2 ratio in immature and mature 
differentiation stage, respectively, so that with rise in 
cell dilution ratio, the effect augmented and vice versa 
(Figure 6). 
 
Figure 4. The effect of UC-MSCs and BM-MSCs on CD1a and CD14 markers in iDCs and mDCs.  
UC-MSCs and BM-MSCs are compared to the control group (in blue). Statistical analysis revealed significant differences in 
UC-MSC and BM-MSC inhibitory effects on CD1a marker on iDCs at dilutions 1:1 (p=0.001), 1:2 (p=0.007) and 1:10 
(p=0.008) and also on mDCs at dilution 1:1 (p=0.01). Differences in UC-MSC enhancing effect on CD14 marker on iDCs at 
dilutions 1:1 (p=0.007), 1:2 (p=0.02) and also on mDCs at dilution 1:1 (p =0.01) were statistically significant. Bars represent 
the mean ±Standard Error (S.E). 
iDC (immature dendritic cell); mDC (mature dendritic cell); BM (Bone marrow); UC (Umbilical cord) 
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Figure 5. The effect of UC-MSCs and BM-MSCs on CD80 and CD86 markers in iDCs and mDCs. UC-MSCs and BM-MSCs 
are compared to the control group (in blue). Differences in UC-MSC and BM-MSC inhibitory effect on CD80 marker on 
iDCs at dilution 1:1 (p=0.04) and on mDCs at dilutions 1:1 (p=0.005) and 1:2 (p=0.025) were statistically significant. 
Differences in UC-MSC inhibitory effect on CD86 marker on iDCs at dilution 1:1 (p=0.01) and on mDCs at dilutions 1:1 
(p=0.001) and 1:2 (p=0.03) were statistically significant. Bars represent the mean ±standard Error (S.E). 
* indicates p < 0.05. 
 
 
 
  
Figure 6. The effect of UC-MSCs and BM-MSCs on CD83 and HLA-DR markers in iDCs and mDCs. UC-MSCs and BM-
MSCs are compared to the control group (in blue). Differences in UC-MSC and BM-MSC inhibitory effect on CD83 marker 
on iDCs at dilution 1:1 (p=0.04) and on mDCs at dilution 1:1 (p=0.007) and 1:2 (p=0.015) were statistically significant. 
Differences in UC-MSC inhibitory effect on HLA-DR marker on mDCs at dilutions 1:1 (p=0.006) and 1:2 (p=0.03) were 
statistically significant. Bars represent the mean ±standard Error (S.E).  
* indicates p < 0.05. 
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Figure 7. The effect of UC-MSCs and BM-MSCs on endocytic activity in iDCs. Differences in UC-MSC and BM-MSC 
inhibitory effects on iDCs at dilution ratio 1:1 (p=0.006) and 1:2 (p=0.02) were statistically significant. Bars represent the 
mean ±standard Error (S.E).  
* indicates p < 0.05. 
 
 
 
The Effect of Secreted Factors from UC-MSCs and 
BM-MSCs on Dendritic Cell Endocytic Activity 
We used transwell culture system (pore size 0.4µm) 
to co-culture iDCs in the absence and presence of UC-
MSCs and BM-MSC. As expected, UC-MSCs were 
capable of declining endocytic activity of iDCs 
(particularly in 1:1 cell dilution ratio) so with increasing 
the dilution ratio, the endocytic activity was positively 
affected and vice versa (Figure 7). 
 
DISCUSSION 
 
UC-MSCs due to their easy preparation, lack of 
expression of the surface antigenic markers such as 
HLA-class ΙΙ, the ability to undergo sustained 
proliferation and the potential to give rise to multiple 
mesenchymal cell lineages, received much more 
attention over the recent years. It has been suggested 
that these cells could be applied in cell therapy and 
regeneration of the damaged biological structures.36-38 
These cells, in spite of their distribution and poor 
quantity in the Wharton’s jelly of the umbilical cord, 
can secrete large amount of growth factors such as 
EGF, TGF-β, IGF-1 and Glial cell-derived 
neurotrophic factor (GDNF) to influence proliferation 
and growth of the other cell populations.15, 24, 39 
Some studies demonstrated that BM-MSCs 
modulate maturation markers and also T lymphocytes35, 
40-46
 and dendritic cell functions47-52 via cell-cell contact 
or secreted factors. This modulatory effect has been 
slightly studied in UC-MSCs rather than BM-MSCs. 
In the present study, we investigated the 
immumodulatory effects of BM-MSCs and UC-MSCs 
on monocyte-derived dendritic cells. In this system, the 
secreted factors from MSCs could cross the transwell 
plate and penetrate to the chamber designated for 
dendritic cells. Our data showed that UC-MSCs like 
BM-MSCs have the same surface marker profile 
(Figure 1). Also UC-MSCs like BM-MSCs can 
differentiate in in vitro conditions to osteocytes and 
adipocytes over 2-3 weeks (Figure 2). 
Interestingly, we observed that UC-MSCs like BM-
MSCs can easily grow and proliferate in DMEM-F12 
medium supplemented with 10% FBS. UC-MSC 
proliferation was clearly much more evident than BM-
MSCs so that we sometimes had to culture the cells 
every 3 days. Although the BM-MSCs changed 
morphologically and their dedifferentiation 
compromised over frequent passages, we cultured UC-
MSCs up to 20 times with no detectable changes in 
shape and their differentiation to osteocytes and 
adipocytes (Figures 2, 3). 
Therefore UC-MSCs may have an extended culture 
capacity compared to BM-MSCs, specifically greater 
than 20 passages. In fact, it has been shown that UC-
MSCs are transitional between embryonic and adult 
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stem cells and possess higher proliferation and 
differentiation rate than BM-MSCs and therefore can 
be helpful in research and clinical applications.11, 25 
In this study, we showed that Co-cultivation of UC-
MSCs and BM-MSCs with monocytes during dendritic 
cell differentiation and maturation period inhibited 
strongly the initial differentiation of CD14+ monocytes 
into CD1a+ DCs via soluble factors which indicate that 
UC-MSCs and BM-MSCs impeded reasonably the 
differentiation of monocytes to immature dendritic cells 
(Figure 4).  
In the case of mature DCs, our data showed that 
UC-MSCs were able to down-regulate expression of 
costimulatory molecules CD80, CD86 and CD83 (a key 
marker in mature dendritic cells) particularly at higher 
dilutions. Hence, modulation of DC differentiation and 
function is relevant to the immunomodulatory effects 
of UC-MSCs. Therefore, their down-regulation caused 
a defect in differentiation of immature dendritic cells to 
mature ones and eventually a deficiency in antigen 
presentation (Figures 5, 6). Nevertheless, the 
modulatory effect led to down-regulation of the other 
dendritic cells’ surface markers which was consistent 
with other studies.47-50, 52 
Also, we found that modulatory effects of UC-
MSCs and BM-MSCs on markers of differentiation, 
maturation and endocytic activity of dendritic cell was 
dose dependent so that with rise in cell dilution ratio 
from 1:1 to 1:10 this effect showed statistically 
significant difference (Figures 4,5,6,7). 
As we know, the main function of DCs is to take up 
and process antigen material and present it on the 
surface to naïve T lymphocytes and other cells of the 
immune system to generate immune responses. 
Immature DCs display a high ability for antigen uptake 
and processing.31, 51, 52  
In this study, we co-cultured monocyte-derived 
iDCs with UC-MSCs and BM-MSCs and analyzed 
their ability to take up fluorescently labeled dextran 
(endocytic activity). We found that UC-MSCs and BM-
MSCs can modulate them to large extent. The 
immunomodulatory effects of UC-MSCs sounded 
much stronger compared to BM-MSCs so that with 
increase in cell dilution ratio, the endocytic activity of 
iDCs decreased and vice versa (Figure 7). 
The ability of DCs to initiate an immune response 
depends on their transition from antigen processing to 
antigen-presenting cells, during which they up-regulate 
class II major histocompatibility complex ІІ (HLA-DR) 
and T-cell costimulatory molecules (CD80,CD86)  
on the cell surface, a process referred to as  
DC maturation.53,54 This transition constitutes an 
important checkpoint in mounting an immune response 
because iDCs not only fail to prime T cells effectively 
but also serve to promote tolerance induction.55,56  
Thus, DCs are critical in the initiation of  
primary immune responses, becoming an important 
target for immunosuppression to prevent allograft 
rejection.57,58 
In general, our data showed that UC-MSCs like 
BM-MSCs possess significant inhibitory effects on 
differentiation and maturation markers and also 
endocytic activity of immature and mature dendritic 
cells. In addition, the isolation of UC-MSCs is easier 
compared to BM-MSCs. These cells proliferate rapidly 
in cell culture flasks to high passage numbers which 
can be eventually frozen. 
In summary,  Our results show that UC-MSCs are 
able to on cell differentiation, expression of surface 
markers of monocyte-derived dendritic cell and antigen 
uptake have a significantly impact. 
 On the other hand, isolation and cultivation of  
UC-MSCs compared to BM-MSCs is easier and with 
less ethical problems. Therefore, UC-MSCs as a new 
source of MSCs could be advantageous for future 
therapeutic and immunomodulatory applications in 
recovery and reduction of autoimmune and 
inflammatory diseases.  
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